AI assistant
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2013
Dec 17, 2013
29977_dirs_2013-12-17_f10af4da-4daf-4328-815d-b1288148954c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2013-12-13
Reporting Person: SCHLEIFER LEONARD S (Director, President & CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2013-12-13 | Non-Qualified Stock Option (right to buy) | $30.63 | A | 187500.0 | Acquired | 2020-12-14 | Common Stock (187500) | Direct |
| 2013-12-13 | Non-Qualified Stock Option (right to buy) | $270.43 | A | 239063.0 | Acquired | 2023-12-13 | Common Stock (239063) | Direct |
Footnotes
F1: On December 14, 2010, the reporting person was granted an option to purchase 187,500 shares of Common Stock. The option vests, partially or in full, on December 31, 2013, based on the extent to which the company satisfies certain performance criteria during the period ending December 31, 2013. The performance criteria have been met and the option will vest as to all 187,500 shares on December 31, 2013.
F2: The stock option award vests in four equal annual installments, commencing one year after the date of grant.